Table 2

Biologic and nonbiologic DMARDs use 30 days before and after zoster vaccination (n = 514)

30 days before vaccination

Day of vaccination

30 days after vaccination

n

%

n

%

n

%


Anti-TNF

40

7.8

32

6.2

40

7.8

Etanercept

18

3.5

12

2.3

18

3.5

Adalimumab

11

2.1

9

1.8

11

2.1

Infliximab

11

2.1

11

2.1

11

2.1

Other biologicsa

4

0.8

4

0.8

4

0.8

Nonbiologic DMARDs

Methotrexate

52

10.1

34

6.6

45

8.8

Sulfasalazine

16

3.1

13

2.5

16

3.1

Hydroxychloroquine

26

5.1

17

3.3

25

4.9

Azathioprine

1

0.2

1

0.2

1

0.2

Leflunomide

3

0.6

3

0.6

3

0.6

Cyclosporine

7

1.4

6

1.2

7

1.4

6-Mercaptopurine

5

1.0

3

0.6

5

1.0

Oral glucocorticoid

45

8.8

33

6.4

48

9.3


DMARDS, Disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; TNF, tumor necrosis factor. aThe categories (columns) are not exclusive (for example, a patient who used anti-TNF therapies continuously during the 60-day period would be counted in all three categories). bAbatacept, rituximab.

Zhang et al. Arthritis Research & Therapy 2011 13:R174   doi:10.1186/ar3497

Open Data